| Vol. 10.14 – 26 April, 2024 |
| |
|
|
| Programmable nanomicelles were designed for colitis treatment and loaded with RU.521, an inhibitor of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. [ACS Nano] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that intestinal-epithelial intrinsic expression of lysine-specific demethylase 1A (LSD1) was necessary for the postnatal maturation of intestinal epithelium and maintenance of this developed state during adulthood. [Nature Communications] |
|
|
|
| The findings unveiled a previously unrecognized role of T-bet in intestinal epithelial cells for inducing apoptosis, diarrhea, and local inflammation, thus implicating its potential as a therapeutic target for the treatment of cancer and inflammatory diseases. [Advanced Science] |
|
|
|
| Researchers established that small-molecule inhibitors of Sirt2 were promising treatment strategies for inflammatory bowel disease. Small-molecule inhibitors of enzymes had been increasingly used to investigate the biological function of enzymes. [Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Lipopolysaccharide-induced Caco2 cells were used to mimic ulceratvie colitis cell models. CircSOD2, miR-378g, and Snail1 levels were determined by quantitative real-time PCR. [Journal Of Gastroenterology And Hepatology] |
|
|
|
| Investigators revealed an unexpected role of leaf-derived morin, which represents molecular signaling targeting the Frizzled7 (FZD7) platform instrumental for controlling intestinal stem cells regeneration upon stable enterotoxin b injury. [Journal Of Agricultural And Food Chemistry] |
|
|
|
|
| The authors present the interactions among the immune system, intestinal barrier, and gut microbiome. Recent advances in administration routes and methods that positively regulate intestinal flora for inflammatory bowel disease have been reviewed. [Journal Of Controlled Release] |
|
|
|
|
| Palisade Bio, Inc. announced the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by ulcerative colitis. [Palisade Bio, Inc.] |
|
|
|
|
| May 17, 2024 Madison, Wisconsin, United States |
|
|
|
|
|
| University of Groningen – Groningen, Netherlands |
|
|
|
|
| Cold Spring Harbor Laboratory – Cold Spring Harbor, New York, United States |
|
|
|
| Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| Monash University – Melbourne, Victoria, Australia |
|
|
|
|